Want to see IN:BALPHARMA full AI Analyst Report?

Bal Pharma Limited (BALPHARMA) Price & Analysis

0 Followers

BALPHARMA Stock Chart & Stats

₹87.08

₹1.29(1.48%)

At close: Jul 27 4:00 PM EDT

₹87.08

₹1.29(1.48%)

Day’s Range― - ―

52-Week Range₹59.69 - ₹112.97

Previous CloseN/A

Volume164.27K

Average Volume (3M)4.08K

Market Cap

₹1.40B

Enterprise Value₹2.92B

Total Cash (Recent Filing)₹92.92M

Total Debt (Recent Filing)₹1.60B

Price to Earnings (P/E)22.2

Beta0.80

Next Earnings

Aug 06, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield1.37%

Share Statistics

EPS (TTM)3.96

Shares Outstanding15,920,872

10 Day Avg. Volume4,315

30 Day Avg. Volume4,084

Financial Highlights & Ratios

PEG Ratio-1.14

Price to Book (P/B)1.17

Price to Sales (P/S)0.31

P/FCF Ratio-23.54

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Diversified Revenue StreamsBal Pharma's business spans finished formulations, APIs and contract manufacturing for third parties, plus domestic and export channels. This multi-pronged model cushions revenue against single-market shocks, supports steady order flow from partners, and sustains cash generation over months to years.

Long‑run Revenue Growth TrendSustained revenue expansion from 2021–2026 indicates expanding market penetration or higher volumes across products and geographies. Even if growth is uneven year-to-year, a multi-year upward trend underpins capacity utilization and supports medium-term planning and investment recovery.

Ongoing Profitability (positive ROE)Consistent positive earnings and mid-single to low-double digit ROE show the business can generate returns on capital. While margins are thin, persistent profitability supports reinvestment, servicing of obligations, and provides a platform for incremental margin improvements or scale benefits over several quarters.

Bears Say

High LeverageLeverage near 1.8x–2.1x and an upward debt trend materially reduces financial flexibility. Elevated interest and principal obligations constrain capital allocation, increase vulnerability to demand or margin shocks, and limit the firm's ability to fund organic growth or cushion working-capital swings over the medium term.

Volatile And Weak Free Cash FlowRecurring swings to deeply negative free cash flow in multiple years signal inconsistent conversion of profits into cash, likely from working-capital pressure or episodic investment. This variability undermines debt servicing ability, raises refinancing risk, and complicates reliable dividend or share-repurchase policies.

Thin, Inconsistent Profitability And Margin VariabilityThin net income and marked swings in gross profit suggest sensitivity to product mix, pricing, or input costs. Such margin variability makes earnings less predictable, weakens cash buffers, and raises execution risk for maintaining profitable growth without structural margin improvements or more stable product economics.

Bal Pharma Limited News

Bal Pharma Rectifies Technical Discrepancies in NSE XBRL Filings

An announcement from Bal Pharma Limited ( ($IN:BALPHARMA) ) is now available. Bal Pharma Limited has clarified discrepancies...

6d ago

BALPHARMA FAQ

What was Bal Pharma Limited’s price range in the past 12 months?

Bal Pharma Limited lowest stock price was ₹59.69 and its highest was ₹112.97 in the past 12 months.

What is Bal Pharma Limited’s market cap?

Bal Pharma Limited’s market cap is ₹1.40B.

When is Bal Pharma Limited’s upcoming earnings report date?

Bal Pharma Limited’s upcoming earnings report date is Aug 06, 2026 which is in 4 days.

How were Bal Pharma Limited’s earnings last quarter?

Bal Pharma Limited released its earnings results on May 27, 2026. The company reported ₹2.26 earnings per share for the quarter, beating the consensus estimate of N/A by ₹2.26.

Is Bal Pharma Limited overvalued?

According to Wall Street analysts Bal Pharma Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Bal Pharma Limited pay dividends?

Bal Pharma Limited pays a Annually dividend of ₹1.2 which represents an annual dividend yield of 1.37%. See more information on Bal Pharma Limited dividends here

What is Bal Pharma Limited’s EPS estimate?

Bal Pharma Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Bal Pharma Limited have?

Bal Pharma Limited has 15,920,872 shares outstanding.

What happened to Bal Pharma Limited’s price movement after its last earnings report?

Bal Pharma Limited reported an EPS of ₹2.26 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 4.544%.

Which hedge fund is a major shareholder of Bal Pharma Limited?

Currently, no hedge funds are holding shares in IN:BALPHARMA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Bal Pharma Limited

Bal Pharma Limited, together with its subsidiaries, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk drugs. It also provides anti-infectives, pain management, respiratory care, and women's health products under the Aziwin, Ebay, Balvibe, MNF, Ocium, and Monogesic Plus Gel brands; diabetic care products under the Diabend and Diabend M Group brands; herbal/ayurvedic preparations targeting conditions, such as prostate enlargement, renal calculi, male infertility, and women health, etc. under the Stonex, Ashwamed, Prostowin, Suswas, Menoleap, and Ayursulin brands; anti-hypertensive, anti-lipidemic, and anti-obese products; skin care and bone health products; herbal liver protective and antioxidant; and cardiac care products under the Secremet and Servace brands. In addition, the company offers a range of APIs for therapeutic areas, such as anti-histamine, platelet inhibitor, anti-diabetic, anti-convulsant, urinary incontinence, neuropathic pain, anti-allergy, anti-inflammatory, diuretic, and acne treatment, etc.; and various formulations, including tablets, capsules, syrups, suspensions, ophthalmic, creams, and ointments. Further, it engages in the treatment of gastrointestinal disorders; and piles, fistula, and constipation. The company exports its products to approximately 30 countries. Bal Pharma Limited was incorporated in 1987 and is based in Bengaluru, India.